Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. Within this 4-part podcast series, experts in the field discuss current therapy dosing schedules and their impact on visual outcomes and patient adherence, assess novel mechanisms of action of emerging therapies that have the potential to improve visual acuity, as well as evaluate new and emerging therapeutic and dosing options that have the potential to reduce treatment burden in patients with nAMD.  Transcription: https://tinyurl.com/Ophthalmology3